paclitaxel

P2, N=138, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed

P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed

No changes in the LVEF or GLS that required treatment interruption occurred, and cardiac biomarkers remained normal. Among patients with HER2-positive early-stage breast cancer who received paclitaxel and trastuzumab, had a preserved baseline LVEF, and had no anthracycline exposure, the cardiotoxicity incidence was low, suggesting that cardiac monitoring may be simplified in this population.

Chemotherapy was the principal treatment (62.12%), with cyclophosphamide (69.62%), doxorubicin (53.80%), and paclitaxel (56.33%) as the most prescribed agents. Significant associations were also observed under the recessive model (AA vs. GG + AG: OR = 1.96, 95% CI = 1.0-3.86, p = 0.051) and the allelic model (A vs G: OR = 1.59, 95% CI = 1.06-2.39, p = 0.026). The miR-218-2 rs11134527 A allele confers an increased risk of breast cancer in Bangladeshi women, supporting its potential role as a population-specific genetic biomarker for susceptibility assessment.

She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.

BA exerts its anti-NSCLC effects via multi-target regulation of oncogenic signaling and metabolic reprogramming. This offers preliminary insights that could inform future applications in metabolic-targeted therapies and combination treatments.

P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=116, Recruiting, Yonsei University | Not yet recruiting --> Recruiting

P3, N=574, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027

The case underscores current controversies in the management of stage III NSCLC and the critical role of the MDT. While neoadjuvant and perioperative chemo-immunotherapy offers an opportunity for less extensive surgical resection and improved oncological outcomes, this strategy is not without risks and validated biomarkers to guide decision making are lacking. Concurrent chemoradiotherapy (cCRT) followed by durvalumab remains the standard for fit patients with unresectable or inoperable stage III disease. Future progress depends on clinical trials, biomarker development, and real-world data collection and national audits.